Skip to main content

Table 1 Non parametric parameters of the three groups on anti-HCV treatment

From: Impact of different anti-HCV regimens on platelet count during treatment in Egyptian patients

  SIM/SOF SOF/RBV Triple p value
Count % Count % Count %
Sex        
 Male 26 45.6% 32 58.2% 38 67.9% 0.057
 Female 31 54.4% 23 41.8% 18 32.1%
Residency        
 Urban 34 59.6% 42 76.4% 35 62.5% 0.138
 Rural 23 40.4% 13 23.6% 21 37.5%
History of previous ttt        
 ttt naïve 54 94.7% 35 64.8% 42 75.0% < 0.001
 ttt experienced 3 5.3% 19 35.2% 14 25.0%
Smoking        
 Yes 6 10.5% 7 12.7% 11 19.6% 0.354
 No 51 89.5% 48 87.3% 45 80.4%
Comorbidities (diabetes and/or hypertension)        
 Yes 21 36.8% 21 38.2% 18 32.1% 0.783
 No 36 63.2% 34 61.8% 38 67.9%
Liver by ultrasound        
 Normal 0 0.0% 2 3.6% 8 14.3% < 0.001
 Cirrhotic 31 54.4% 47 85.5% 25 44.6%
 Abnormal echopattern 26 45.6% 6 10.9% 23 41.1%
Spleen by ultrasound        
 Enlarged 28 49.1% 41 74.5% 35 62.5% 0.021
 Average 29 50.9% 14 25.5% 21 37.5%
Ascites by ultrasound        
 Yes 0 0.0% 1 1.8% 1 1.8% 0.549
 No 57 100.0% 54 98.2% 55 98.2%
Child score calculation        
 A5 25 43.9% 26 47.3% 50 89.3% < 0.001
 A6 32 56.1% 21 38.2% 4 7.1%
 B7 0 0.0% 7 12.7% 2 3.6%
 B8 0 0.0% 1 1.8% 0 0.0%
Stage of fibrosis        
 F1 3 27.3% 1 4.0% 2 8.0% 0.003
 F2 1 9.1% 1 4.0% 0 0.0%
 F3 1 9.1% 4 16.0% 14 56.0%
 F4 6 54.5% 18 72.0% 9 36.0%
 F5 0 0.0% 1 4.0% 0 0.0%
Stage of necroinflammatory activity        
 A1 1 50.0% 2 25.0% 4 33.3% 0.749
 A2 1 50.0% 4 50.0% 7 58.3%
 A3 0 0.0% 1 12.5% 0 0.0%
 A7 0 0.0% 0 0.0% 1 8.3%
 A10 0 0.0% 1 12.5% 0 0.0%
Week 4 HCV RNA by PCR        
 Positive 3 5.3% 7 12.7% 2 3.6% 0.183
 Negative 54 94.7% 48 87.3% 54 96.4%
Week 12 HCV RNA by PCR        
 Positive 2 3.6% 1 1.8% 0 0.0% 0.325
 Negative 53 96.4% 54 98.2% 56 100.0%
HCV antiviral dose modification        
 No 57 100.0% 54 98.2% 51 91.1% 0.025
 Modified 0 0.0% 1 1.8% 5 8.9%